|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Analyst Conference Summaries |
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Avidity Biosciences
|
2022 | |||
Avidity Biosciences Q4 2021 |
Avidity Biosciences Q1 2022 |
||
March 1, 2022 | May 10, 2022 | ||
2021 | |||
Avidity Biosciences Q4 2020 |
Avidity Biosciences Q1 2021 |
Avidity Biosciences Q2 2021 Press Release |
Avidity Biosciences Q3 2021 summary |
March 16, 2021 | May 12, 2021 | August 9, 2021 | November 9, 2021 |
Avidity Biosciences (RNA) is a preclinical-stage biotechnology company specializing in a novel RNA therapy platform for diseases caused by genetic mutations.
More Analyst Conference Pages:
AGEN |
AGIO |
ALNY |
ALXN |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BMY |
CLDX |
DRNA |
EPZM |
GILD |
GLYC |
ILMN |
INO |
IONS |
ISRG |
MCHP |
MRNA |
PLX |
REGN |
SAGE |
SGEN |
VBLT |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2021 William P. Meyers